# EDGAR Filing Document

**Accession Number:** 0001395064
**File Stem:** 0001395064-25-000113
**Filing Date:** 2025-7
**Character Count:** 10788
**Document Hash:** b79fb3d47c41db17c2520ef4bdfff936
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001395064-25-000113.hdr.sgml**: 20250708

**ACCESSION NUMBER**: 0001395064-25-000113

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250708

**FILED AS OF DATE**: 20250708

**DATE AS OF CHANGE**: 20250708

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TAKEDA PHARMACEUTICAL CO LTD
- **CENTRAL INDEX KEY:** 0001395064
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38757
- **FILM NUMBER:** 251109476

**BUSINESS ADDRESS:**
- **STREET 1:** 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU
- **CITY:** TOKYO
- **STATE:** M0
- **ZIP:** 103-8668
- **BUSINESS PHONE:** 81332782111

**MAIL ADDRESS:**
- **STREET 1:** 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU
- **CITY:** TOKYO
- **STATE:** M0
- **ZIP:** 103-8668

**FORM 6-K**

**U.S. SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of**

**the Securities Exchange Act of 1934**

**For the month of July 2025**

**Commission File Number: 001-38757**

**TAKEDA PHARMACEUTICAL COMPANY LIMITED**

**(Translation of registrant's name into English)**

**1-1, Nihonbashi-Honcho 2-Chome**

**Chuo-ku, Tokyo 103-8668**

**Japan**

**(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

------

Information furnished on this form:

**EXHIBIT**

---

| | |
|:---|:---|
| Exhibit<br>Number | |
| 1 | <u>[Takeda Completes Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees](#if2cfc345874a4dcab17dfc2637f27037_85)</u> |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **TAKEDA PHARMACEUTICAL COMPANY LIMITED** | **TAKEDA PHARMACEUTICAL COMPANY LIMITED** |
| Date: July 8, 2025 | By: | /s/ Norimasa Takeda |
|  |  | Norimasa Takeda<br>Chief Accounting Officer and Corporate Controller |

---

------

Statement

**Takeda Completes Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees**

**Osaka, JAPAN and CAMBRIDGE, Massachusetts, July 8, 2025 –** Takeda ("Company") announced that it completed the disposal of treasury shares today, under the Long-Term Incentive Plan for the Company Group employees outside of Japan.

In addition, the number of shares originally planned for disposal, and other relevant figures, have been changed due to a partial forfeiture of rights granted to previously planned allotees, as outlined below.

For the details, please refer to the announcement dated June 10, 2025, "Notice Concerning Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan".

&nbsp;&nbsp;&nbsp;&nbsp;1.Changes in Outline of Disposal of Shares (Changes are underlined)

---

| | | |
|:---|:---|:---|
|  | After the change | Before the change |
| (1)&nbsp;&nbsp;&nbsp;&nbsp;Payment date | July 8, 2025 | July 8, 2025 |
| (2)&nbsp;&nbsp;&nbsp;&nbsp;Type and number of shares to be disposed of | Shares of common stock in the Company; numbering <u>17,270,941</u> shares | Shares of common stock in the Company; numbering <u>17,355,770</u> shares |
| (3)&nbsp;&nbsp;&nbsp;&nbsp;Disposal price | 4,336 yen per share | 4,336 yen per share |
| (4)&nbsp;&nbsp;&nbsp;&nbsp;Total value of shares to be disposed of | <u>74,886,800,176</u> yen | <u>75,254,618,720</u> yen |
| (5)&nbsp;&nbsp;&nbsp;&nbsp;Planned allottee | Employees of the Company and Company's subsidiaries; numbering <u>10,283</u> persons: <u>17,270,941</u> shares | Employees of the Company and Company's subsidiaries; numbering <u>10,346</u> persons: <u>17,355,770</u> shares |

---

&nbsp;&nbsp;&nbsp;&nbsp;2.Reason for the Change

The change in the number of shares for disposal and other relevant figures is due to the forfeiture of part or all of rights granted to the allotees as previously planned at the time of the decision on the disposal of shares.

&nbsp;&nbsp;&nbsp;&nbsp;3.Outlook

The above changes will have immaterial impact on the full-year financials for the Company's fiscal year ending on March 31, 2026.

------

**About Takeda**

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

**Contacts**

---

| | |
|:---|:---|
| **Investor Relations**<br>Christopher O'Reilly<br>christopher.oreilly@takeda.com<br>+81 (0) 90-6481-3412 | **Media Relations**<br>Brendan Jennings<br>brendan.jennings@takeda.com<br>+81 (0) 80-2705-8259 |

---

**Important Notice**

For the purposes of this notice, "statement" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this release. This statement (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this statement. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This statement is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this statement, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words "we", "us" and "our" are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

**Forward-Looking Statements**

This statement and any materials distributed in connection with this statement may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could", "anticipates", "estimates", "projects", "forecasts", "outlook" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of

------

marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this statement or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this statement may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results.

**###**

<br>